



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Review article

Will Mayaro virus be responsible for the next outbreak of an arthropod-borne virus in Brazil?



Danillo Lucas Alves Esposito, Benedito Antonio Lopes da Fonseca*

Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Clínica Médica, Ribeirão Preto, SP, Brazil

ARTICLE INFO

Article history:

Received 20 February 2017
Accepted 11 June 2017
Available online 7 July 2017

Keywords:

Mayaro virus
Alphavirus
Chikungunya virus
Epidemiology
Outbreaks

ABSTRACT

Mayaro virus is an alphavirus from the *Togaviridae* family and is transmitted mainly by *Hemagogus* mosquitoes. This virus circulates in high-density tropical forests or rural areas of Central and South America causing a disease characterized by high-grade fever, maculopapular skin rash and marked arthralgia that, in some patients, can persist for long periods after infection and may be misinterpreted as chikungunya. Although only a few outbreaks involving this virus have been reported, in the last years the number of Mayaro virus infections has increased in the central and northern regions of Brazil. In this review, we describe the reported prevalence of this infection over the years and discuss the circumstances that can contribute to the establishment of an urban mayaro virus epidemic in Brazil and the problems encountered with the specific diagnosis, especially the antigenic cross-reactivity of this pathogen with other viruses of the same family.

© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Mayaro virus (MAYV; genus *Alphavirus*, family *Togaviridae*) is an arbovirus transmitted primarily by the bite of female mosquitoes of the genus *Hemagogus*, usually from an infected non-human primate (monkeys) to a susceptible human. These tree-dwelling mosquitoes are also the vectors involved in the sylvatic cycle of yellow fever virus, and although MAYV maintenance efficiency in primary reservoirs is not known, it has been detected in nature in several vertebrate hosts such as non-human primates, rodents, birds, sloths, and other small mammals.¹

As for yellow fever virus, MAYV can infect humans who inhabit the rural areas or enter these forested areas either to work or to take advantage of the environmental attractions, leading to a febrile condition characterized by fever,

cutaneous rash, and joint pain. In recent years, there has been an increased number of cases of mayaro fever in several Brazilian states and with the increased circulation of chikungunya virus, there is always a question as to whether a febrile exanthematous disease with severe joint involvement is due to chikungunya or MAYV. In this review, based on epidemiologic and laboratory data, we discuss the variables involved in the possible establishment of outbreaks caused by MAYV.

The virus

MAYV genome is composed of a single-stranded positive-sense RNA of approximately 12 kb in size, flanked by a

* Corresponding author.

E-mail address: baldfon@fmrp.usp.br (B.A. Fonseca).
<http://dx.doi.org/10.1016/j.bjid.2017.06.002>

1413-8670/© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. 1 – A schematic Mayaro virus genome organization and its replication complex.

5'-7-methylguanylate (m^7G) cap and a 3'-poly-A tail. It encodes four nonstructural proteins (nsP1–4) and five structural proteins (C-E3-E2-6k-E1).² Similar to other alphaviruses, MAYV RNA has a stop codon at the end of nsP3 gene, and at a low frequency (5–20%), a read-through translation can occur, resulting in nsP1–4 product (Fig. 1). Structural proteins are produced after translation of a subgenomic RNA transcript, synthesized from the negative-sense RNA used for replication, a common feature of the *Togaviridae* family³ (Fig. 1). Following the expression of structural proteins, the virus RNA is complexed to the capsid protein and the envelope proteins, processed during their traffic through the Golgi apparatus, are inserted into the plasma membrane from where the virus acquires its envelope, releasing infectious particles able to infect susceptible cells.

Phylogenetically, MAYV is considered a monophyletic group, divided in two similar genotypes—genotype D, which includes most of the isolates, from 1954 to 2003, and genotype L, limited to the Brazilian isolates.⁴ MAYV is part of the Semliki Complex, a serological group inside *Alphavirus* genus that shares some common antigenic sites, which can generate cross-reactivity with polyclonal immune sera among the species, when analyzed by conventional serological tests, such as Hemagglutinin Inhibition (HI) and Complement Fixation (CF). The Semliki Complex is composed by eight viruses (Bebaru, Chikungunya, Mayaro, Getah, Semliki Forest, Ross River, O'nyong-nyong, and Una viruses) of veterinary and medical importance, usually causing human disease characterized by fever, arthritis and skin rash⁵ (Fig. 2 – the strain of MAYV used to assemble this phylogeny was BeAr20290⁶). As mentioned before, the fact that these viruses belong to the same serological complex, the correct diagnosis of these infections can be difficult to achieve, usually only carried out in well-equipped research laboratories. Specifically, of importance to Brazil, chikungunya and mayaro fever can exhibit the same clinical manifestations and both viruses are co-circulating in the country.

Clinical manifestations and specific diagnosis

Little is known about the pathophysiology of mayaro fever, but once the infection has established the virus goes through

an intrinsic incubation period, which can range from 3 to 11 days, when a high-rate replication takes place followed by a short viremia lasting while the symptoms are present (usually 5–7 days). The symptoms of MAYV infection are often an exanthematous rash, fever, myalgia, retro-orbital pain, headache, diarrhea, and arthralgia, the latter may persist for months or even years.⁷ There are several reports on the literature of persistent or recurrent arthralgia resulting from MAYV infection,^{8–10} which could be a result of an inefficient neutralizing antibody response against this virus associated with the continuous expression of some pro-inflammatory immune cytokines.¹¹ However, there is a need for more studies evaluating the broad spectrum of the clinical manifestations of the acute phase of the disease, including unusual presentations, if present, as well as the possible chronic clinical manifestations, and also, the viral and immunological parameters involved in the causation of each form of this disease.

As for most arboviral infections, the diagnosis of alphavirus infection, such as Mayaro fever, is more efficient if performed during the acute phase of the disease, either by virus isolation or RT-PCR to detect viral RNA. At a convalescent phase of infection, antibody cross-reactivity has been shown to occur when using traditional serological tests, such as ELISA. High cross-reactivity between mayaro and chikungunya has been described,^{12,13} and either side-by-side tests aiming at the comparison of serum reactivity to each virus or neutralization tests should be performed to correctly establish the specificity of an antibody reaction, and provide a correct diagnosis of the disease.

Epidemiology

The epidemiologic history of MAYV infection begins in 1954 with its first report in Trinidad and Tobago, when the virus was isolated from blood samples of five rural workers that presented with a febrile disease. The virus received its name after Mayaro County, a southeastern region of Trinidad, where the cases were reported.¹⁴ Since then, the virus has been reported in some countries in Central and South America, usually in places with tropical forests, such as French Guiana, Bolivia, Peru, Suriname, Costa Rica, Guatemala, Venezuela, Mexico, Ecuador, Guyana, Panama, and Brazil. Imported cases are not very frequent, but some have been reported: North Americans

replication not only *in vitro*, but *in vivo*, and then, transmit the virus.^{30,31} Similar to *Ae. albopictus*, *Ae. aegypti* showed to be an effective vector to transmit MAYV. After laboratory infection of mosquitoes, the virus could be found in the salivary glands and could be successfully transmitted to mice, at a high rate of infection.³² In addition to laboratory infection of *Aedes* mosquitoes by MAYV, Serra et al.³³ found MAYV-infected *Ae. aegypti* and *Culex quinquefasciatus* in their natural habitats, in Cuiabá, Mato Grosso, Brazil. All these findings underscore the possibility of MAYV infection of *Aedes* sp. mosquitoes and the transmission cycle of this virus may shift from sylvatic to urban, using humans as amplifying hosts, and then establishing new outbreaks in Brazil, since the majority of the Brazilian population is susceptible to MAYV infection.

Prevention and control of MAYV infections

There is no antiviral against MAYV and only symptoms are treated, similar to treatment available for chikungunya virus infection, with the initial prescription of nonsteroidal anti-inflammatory drugs and analgesics for pain and fever relief, and sometimes corticosteroids, although its efficacy has not been fully proven.³⁴ Not much data is available on MAYV treatment, but drugs and therapies are administered similar to other alphavirus infections that have a clinical course comparable to mayaro infection, such as chikungunya and Ross River viruses.

No commercial vaccines are available, but two candidates were tested in pre-clinical experiments. The first attempt generated inactivated particles, using different concentrations of formalin and showed to be immunogenic when administered in mouse, with some efficacy.³⁵ Another candidate was a live attenuated vaccine, that could replicate in vertebrate cells, but not in mosquitoes, with mutations in sub-genomic promoter and translational control of an internal ribosomal site (IRES) from encephalomyocarditis virus (EMCV), which demonstrated a great production of neutralizing antibodies and a high rate of survival after challenge, using immunocompetent mice.³⁶

Conclusion

MAYV is the cause of an emergent infection in Central and South America, and similar to what happened to zika and chikungunya viruses, it has the potential to establish an epidemic scenario in Brazil. Although there is no evidence of the transmission efficiency of MAYV in an urban cycle, the susceptibility of the population to this infection, in addition to the possibility of transmission of this pathogen by *Aedes* mosquitoes, widely distributed in Brazil, can increase the number of infected individuals. Due to its antigenic similarity with chikungunya virus, it is clear the urgency for the development of specific and accurate diagnostic methods for a better diagnosis of MAYV infections. In the possession of accurate diagnostic tests, it will be possible to distinguish the infections caused by MAYV from other arboviral infections and define the real importance of MAYV to the Brazilian public health and to define the complete picture of mayaro fever clinical manifestations.

Since 2014, a growing epidemic of chikungunya virus infection is occurring in Brazil. Data from the Brazilian Ministry of Health show almost a 10-fold increase of suspected cases occurred in Brazil, from the year of 2015 to 2016 (38,499 to 265,554 cases, respectively),³⁷ with most of the cases being reported in the northern and northeastern regions of the country, where MAYV is endemic. Most of these cases were diagnosed by a clinical-epidemiological criterion, since there are no reliable and specific serological tests to confirm the infection. Considering that no difference can be found in symptoms from both infections, the number of cases of mayaro fever could be underestimated and many of the chikungunya cases were really MAYV infections.

In terms of controlling possible mayaro fever outbreaks, since there is no vaccine to suppress the spread of this disease, the only current approach is vector control. However, this approach has proved so far inefficient, in the view of the increasing number of new arboviral infections (dengue, zika, chikungunya, and even mayaro) in the country in the last years. Finally, in order to lower the importance of these diseases to public health, it is of paramount importance the development of a vaccine or an antiviral treatment to alphavirus infections, due to the impact mayaro and chikungunya fever may have on the quality of life of people infected with these viruses.

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

1. de Thoisy B, Gardon J, Salas RA, Morvan J, Kazanji M. Mayaro virus in wild mammals, French Guiana. *Emerg Infect Dis.* 2003;9:1326-9.
2. Auguste AJ, Liria J, Forrester NL, et al. Evolutionary and ecological characterization of Mayaro virus strains isolated during an outbreak, Venezuela, 2010. *Emerg Infect Dis.* 2015;21:1742-50.
3. ten Dam E, Flint M, Ryan MD. Virus-encoded proteinases of the Togaviridae. *J Gen Virol.* 1999;80 Pt 8:1879-88.
4. Powers AM, Aguilar PV, Chandler LJ, et al. Genetic relationships among Mayaro and Una viruses suggest distinct patterns of transmission. *Am J Trop Med Hyg.* 2006;75:461-9, 75/3/461 [pii].
5. Griffin DE. Alphaviruses. In: Knipe DM, Howley PM, Griffin DE, editors. *Field's virology*. vol. 2 Philadelphia: Lippincott Williams & Wilkins; 2013.
6. Esposito DL, da Fonseca BA. Complete genome sequence of Mayaro virus (Togaviridae, Alphavirus) strain BeAr 20290 from Brazil. *Genome Announc.* 2015;3, <http://dx.doi.org/10.1128/genomeA.01372-15>.
7. Pinheiro FL, LeDuc JW. Mayaro virus disease. In: Monath TP, editor. *The arboviruses: epidemiology and ecology*. vol. 3 Boca Raton, FL: CRC Press; 1998. p. 137-50.
8. Halsey ES, Siles C, Guevara C, et al. Mayaro virus infection, Amazon Basin region, Peru, 2010-2013. *Emerg Infect Dis.* 2013;19:1839-42.
9. Slegers CA, Keuter M, Gunther S, Schmidt-Chanasit J, van der Ven AJ, de Mast Q. Persisting arthralgia due to Mayaro virus infection in a traveler from Brazil: is there a risk for

- attendants to the 2014 FIFA World Cup? *J Clin Virol*. 2014;60:317-9.
10. Taylor SF, Patel PR, Herold TJ. Recurrent arthralgias in a patient with previous Mayaro fever infection. *South Med J*. 2005;98:484-5.
 11. Santiago FW, Halsey ES, Siles C, et al. Long-Term arthralgia after Mayaro virus infection correlates with sustained pro-inflammatory cytokine response. *PLoS Negl Trop Dis*. 2015;9:e0004104.
 12. Hassing RJ, Leparc-Goffart I, Tolou H, van Doornum G, van Genderen PJ. Cross-reactivity of antibodies to viruses belonging to the Semliki forest serocomplex. *Euro Surveill*. 2010;15.
 13. Prat CM, Flusin O, Panella A, Tenebray B, Lanciotti R, Leparc-Goffart I. Evaluation of commercially available serologic diagnostic tests for chikungunya virus. *Emerg Infect Dis*. 2014;20:2129-32.
 14. Anderson CR, Downs WG, Wattley GH, Ahin NW, Reese AA. Mayaro virus: a new human disease agent. II. Isolation from blood of patients in Trinidad, B.W.I. *Am J Trop Med Hyg*. 1957;6:1012-6.
 15. Tesh RB, Watts DM, Russell KL, et al. Mayaro virus disease: an emerging mosquito-borne zoonosis in tropical South America. *Clin Infect Dis*. 1999;28:67-73.
 16. Llagonne-Barets M, Icard V, Leparc-Goffart I, et al. A case of Mayaro virus infection imported from French Guiana. *J Clin Virol*. 2016;77:66-8.
 17. Receveur MC, Grandadam M, Pistone T, Malvy D. Infection with Mayaro virus in a French traveller returning from the Amazon region, Brazil, January, 2010. *Euro Surveill*. 2010;15.
 18. Theilacker C, Held J, Allering L, et al. Prolonged polyarthralgia in a German traveller with Mayaro virus infection without inflammatory correlates. *BMC Infect Dis*. 2013;13:369.
 19. Neumayr A, Gabriel M, Fritz J, et al. Mayaro virus infection in traveler returning from Amazon Basin, northern Peru. *Emerg Infect Dis*. 2012;18:695-6.
 20. Hassing RJ, Leparc-Goffart I, Blank SN, et al. Imported Mayaro virus infection in the Netherlands. *J Infect*. 2010;61:343-5.
 21. Coimbra TL, Santos CL, Suzuki A, et al. Mayaro virus: imported cases of human infection in Sao Paulo State, Brazil. *Rev Inst Med Trop Sao Paulo*. 2007;49:221-4.
 22. Mota MT, Vedovello D, Estofolete C, Malossi CD, Araujo JP Jr, Nogueira ML. Complete Genome Sequence of Mayaro Virus Imported from the Amazon Basin to Sao Paulo State, Brazil. *Genome Announc*. 2015;3, <http://dx.doi.org/10.1128/genomeA.01341-15>.
 23. Causey OR, Maroja OM. Mayaro virus: a new human disease agent. III. Investigation of an epidemic of acute febrile illness on the river Guama in Para, Brazil, and isolation of Mayaro virus as causative agent. *Am J Trop Med Hyg*. 1957;6:1017-23.
 24. Pinheiro FP, Freitas RB, Travassos da Rosa JF, Gabbay YB, Mello WA, LeDuc JW. An outbreak of Mayaro virus disease in Belterra, Brazil. I. Clinical and virological findings. *Am J Trop Med Hyg*. 1981;30:674-81.
 25. Vasconcelos PFC, Travassos da Rosa APA, Pinheiro FP, et al. Arboviruses pathogenic for man in Brazil. In: Travassos da Rosa APA, Vasconcelos PFC, Travassos da Rosa JFS, editors. An overview of arbovirology in Brazil and neighbouring countries. Belém: Instituto Evandro Chagas; 1998. p. 72-99.
 26. Azevedo RS, Silva EV, Carvalho VL, et al. Mayaro fever virus, Brazilian Amazon. *Emerg Infect Dis*. 2009;15:1830-2.
 27. Mourao MP, Bastos Mde S, de Figueiredo RP, et al. Mayaro fever in the city of Manaus, Brazil, 2007-2008. *Vector Borne Zoonotic Dis*. 2012;12:42-6.
 28. Zuchi N, Heinen LB, Santos MA, Pereira FC, Shlessarenko RD. Molecular detection of Mayaro virus during a dengue outbreak in the state of Mato Grosso, Central-West Brazil. *Mem Inst Oswaldo Cruz*. 2014;109:820-3.
 29. Ministério da Saúde. Situação epidemiológica Mayaro; 2017. Available at: <http://portalsaude.saude.gov.br/index.php/o-ministerio/principal/leia-mais-o-ministerio/1205-secretaria-svs/vigilancia-de-a-a-z/febre-do-mayaro/20950-situacao-epidemiologica-dados>
 30. Smith GC, Francy DB. Laboratory studies of a Brazilian strain of *Aedes albopictus* as a potential vector of Mayaro and Oropouche viruses. *J Am Mosq Control Assoc*. 1991;7:89-93.
 31. Mitchell CJ. Vector competence of North and South American strains of *Aedes albopictus* for certain arboviruses: a review. *J Am Mosq Control Assoc*. 1991;7:446-51.
 32. Long KC, Ziegler SA, Thangamani S, et al. Experimental transmission of Mayaro virus by *Aedes aegypti*. *Am J Trop Med Hyg*. 2011;85:750-7.
 33. Serra OP, Cardoso BF, Ribeiro AL, Santos FA, Shlessarenko RD. Mayaro virus and dengue virus 1 and 4 natural infection in culicids from Cuiaba, state of Mato Grosso, Brazil. *Mem Inst Oswaldo Cruz*. 2016;111:20-9.
 34. Figueiredo ML, Figueiredo LT. Emerging alphaviruses in the Americas: Chikungunya and Mayaro. *Rev Soc Bras Med Trop*. 2014;47:677-83.
 35. Robinson DM, Cole FE Jr, McManus AT, Pedersen CE Jr. Inactivated Mayaro vaccine produced in human diploid cell cultures. *Mil Med*. 1976;141:163-6.
 36. Weise WJ, Hermance ME, Forrester N, et al. A novel live-attenuated vaccine candidate for Mayaro fever. *PLoS Negl Trop Dis*. 2014;8:e2969.
 37. Ministério da Saúde. Boletim Epidemiológico, vol. 48. Secretaria de Vigilância Em Saúde - Ministério Da Saúde; 2017. Available at: http://portal.arquivos.saude.gov.br/images/pdf/2017/janeiro/12/2017_001-Dengue_SE51-publicacao.pdf